Cyril Melvin
Internal Medicine · Cincinnati, OHNPI 1558460204
Payments from drug & device makers
Across 106 payments — averaging $188.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$19K
- Novo Nordisk$257
- AstraZeneca$211
- Lilly USA, LLC$129
- Sanofi-aventis U.S. LLC$118
- Novartis$111
- plus $297 from 11 others
What the payments were for
- Speaking & faculty fees$18,45092%
- Travel & lodging$1741%
- Food & beverage$1,3987%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $18,906 |
| Novo Nordisk | 22 | $257 |
| AstraZeneca | 7 | $211 |
| Lilly USA, LLC | 8 | $129 |
| Sanofi-aventis U.S. LLC | 10 | $118 |
| Novartis | 7 | $111 |
| Pfizer | 6 | $77 |
| Merck | 3 | $37 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| AbbVie | 3 | $33 |
| Amarin Pharma, Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $16 |
| GSK | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Metuchen Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,029 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $11,744 |
| TrulicityDulaglutide | 11 | $9,818 |
| Atorvastatin Calcium | 26 | $180 |
| Warfarin Sodium | 16 | $173 |
| Allopurinol | 16 | $156 |
| Buspirone Hcl | 15 | $145 |
| Alprazolam | 28 | $139 |
| Amlodipine Besylate | 16 | $133 |
| Pantoprazole Sodium | 15 | $79 |
| Gabapentin | 13 | $76 |
| Diazepam | 16 | $53 |
| Furosemide | 15 | $50 |
| Metformin Hcl | 16 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $16 | $11,74412 claims |
| Lilly USA, LLCTrulicity | $129 | $9,81811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cincinnati
- Antoinette PragalosCincinnati$27.8M
- Charles EgerCincinnati$8.7M
- Douglas LoganCincinnati$4.7M
- Leela VrishabhendraCincinnati$3.4M
- Traci TurnerCincinnati$645K
- Vincent MartinCincinnati$398K
- Lisa LarkinCincinnati$276K
- Mark EckmanCincinnati$255K
- Kay JohnsonCincinnati$184K
- Steven FolkerthBeavercreek$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.